Biotechnology News and Research

RSS

Crescendo Biologics raises funds to advance the development of its fragment antibody technology platforms

Crescendo Biologics today announces it has raised GBP4.5 million in a seed-funding round to advance the development of its fragment antibody technology platforms. The funding round was led by Sofinnova Partners, a Paris-based venture capital firm, with Aitua, Avlar BioVentures and the Rainbow Seed Fund also participating.

12 Oct 2009

Locus Pharmaceuticals enters into discovery research collaboration with Novartis

Locus Pharmaceuticals announced today that it has entered into a discovery research collaboration with Novartis. Locus will collaborate with Novartis to discover novel chemotypes on targets of interest to Novartis’ select therapeutic areas.

12 Oct 2009

Presentations on efficacy of interferon to combat influenza

Amarillo Biosciences, Inc. (ABI) today announced that Professor Dr. Otto Haller from the Department of Virology, Freiburg University, Germany and Professor Dr. Oliver Planz from the Friedrich Loeffler Institute, Tubingen, Germany gave two separate presentations on the efficacy of interferon to combat influenza.

12 Oct 2009

Mediacorp Canada selects MDS Nordion as one of Canada's Top 100 Employers for 2010

MDS Nordion, a leading provider of medical isotopes and radiopharmaceuticals, has been selected as one of Canada's Top 100 Employers for 2010 by Mediacorp Canada, the nation's largest publisher of employment-related periodicals and online directories.

9 Oct 2009

Czura Thornton to buy MDS' Central Labs operation

MDS Inc., a leading provider of products and services to the global life sciences markets, today announced that it has signed an agreement to sell its Central Labs operation, which conducts analysis of samples from late-stage clinical trials to Czura Thornton, a private investment group based in Jersey, Channel Islands.

From Danaher 9 Oct 2009

Medicago receives contract from U.S. Army Research, Development and Engineering Command laboratory

Medicago Inc. (TSX-V: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has been awarded a proof of concept contract by the U.S. Army Research, Development and Engineering Command laboratory specifically the Edgewood Chemical Biological Center ("ECBC") Research & Technology Directorate.

9 Oct 2009

Czura Thornton to acquire MDS's Central Labs operation

From Danaher 9 Oct 2009

International symposium examines how new advances in plant science research can benefit African agriculture

This three-day international symposium is designed to bring together scientists from Africa, Europe and the USA to examine how new advances in plant science research and developing technologies can be used to the benefit of African agriculture

9 Oct 2009

New York Governor participates in roundtable discussion on stem cell research

Albert Einstein College of Medicine of Yeshiva University hosted a roundtable discussion on stem cell research with New York Governor David A. Paterson today. Allen M. Spiegel, M.D., the Marilyn and Stanley M. Katz Dean of Einstein, and eight stem cell researchers discussed advances in medical therapies and treatments that Einstein scientists have been investigating since receiving more than $14 million in State funding for stem cell research.

9 Oct 2009

Fight against obesity and heart disease gets new boost from public sector and industry

The battle against obesity, heart disease and other diet related health problems received a -4 Million boost today with the announcement of seven new research projects. The projects, taking place in universities and research institutes across the UK, are part of a partnership between two publicly-funded Research Councils and 15 companies.

9 Oct 2009

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Plexxikon Inc. today announced that dosing of cancer patients with PLX3397 has started in a Phase 1 clinical trial. PLX3397 is a novel, oral investigational drug for treating multiple diseases, including metastatic cancer and rheumatoid arthritis.

9 Oct 2009

NHLBI grants for diagnosis and treatment of cardiovascular and blood disorders

Two teams led by Massachusetts General Hospital (MGH) researchers, also members of the Harvard Stem Cell Institute (HSCI), are among 18 groups receiving National Heart Lung and Blood Institute (NHLBI) grants for the development of stem-cell based tools and treatments to understand and treat cardiovascular and blood disorders.

9 Oct 2009

Pro Lab Marketing receives distribution rights for Vivakor’s VivaThermic cryovials in India

Vivakor, Inc. announces distribution of its VivaThermic products to the rapidly growing biotech/biopharma industries in India through its agreement with Pro Lab Marketing Pvt. Ltd.

9 Oct 2009

HST Global announces alliance for R&D of Nutraceutical and Medical Food formulation platform

HST Global, Inc. today announced a strategic R&D alliance with Dr. James W. Forsythe for the research and development of HST’s exclusive Nutraceutical and Medical Food formulation platform.

9 Oct 2009

U.S. army Phase I STTR contract for Intralytix

Intralytix, Inc. announced today that it has received a U.S. Army Phase I STTR contract supporting the development of a bacteriophage-based probiotic preparation for managing Shigella infections.

9 Oct 2009

CHI announces its agenda for the 2009 California Healthcare Policy Forum

CHI-California Healthcare Institute today announced its agenda and newly confirmed speakers for the 2009 California Healthcare Policy Forum to be held Nov. 5, at the InterContinental Mark Hopkins San Francisco Hotel, from 11:30 a.m. to 6:00 p.m.

9 Oct 2009

Applied Neurosolutions provides update regarding its blood-based Alzheimer’s test

Applied NeuroSolutions, Inc.(www.AppliedNeuroSolutions.com), a biotechnology company focused on the development of products for the early diagnosis and treatment of Alzheimer's disease ("AD"), today confirmed, as previously disclosed in July 2009, that it has achieved sufficient analytical sensitivity to detect tau in serum patient samples.

9 Oct 2009

Transgenomic adds DFCI's Cold-PCR mutation detection technology to its portfolio

Transgenomic, Inc. (OTC Bulletin Board: TBIO). The company announced today that it has licensed a high-sensitivity mutation detection technology called Cold-PCR from the Dana-Farber Cancer Institute (DFCI), Boston, MA.

9 Oct 2009

Angiochem to announce clinical study results of ANG1005 drug

Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that clinical data for its lead drug candidate, ANG1005, for the treatment of brain cancers, as well as data showing how compounds from Angiochem’s Engineered Peptide Compounds (EPiC) platform are capable of crossing the blood-brain barrier will be highlighted at the Society for Neuroscience Annual Meeting in Chicago on October 17-21, 2009.

8 Oct 2009

Helicos Biosciences awarded a $2.9M NIH grant

Helicos BioSciences Corporation announced today that it is the recipient of an award from the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH).

8 Oct 2009

Biotechnology News and Research

Crescendo Biologics raises funds to advance the development of its fragment antibody technology platforms

Locus Pharmaceuticals enters into discovery research collaboration with Novartis

Presentations on efficacy of interferon to combat influenza

Mediacorp Canada selects MDS Nordion as one of Canada's Top 100 Employers for 2010

Czura Thornton to buy MDS' Central Labs operation

Medicago receives contract from U.S. Army Research, Development and Engineering Command laboratory

Czura Thornton to acquire MDS's Central Labs operation

International symposium examines how new advances in plant science research can benefit African agriculture

New York Governor participates in roundtable discussion on stem cell research

Fight against obesity and heart disease gets new boost from public sector and industry

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

NHLBI grants for diagnosis and treatment of cardiovascular and blood disorders

Pro Lab Marketing receives distribution rights for Vivakor’s VivaThermic cryovials in India

HST Global announces alliance for R&D of Nutraceutical and Medical Food formulation platform

U.S. army Phase I STTR contract for Intralytix

CHI announces its agenda for the 2009 California Healthcare Policy Forum

Applied Neurosolutions provides update regarding its blood-based Alzheimer’s test

Transgenomic adds DFCI's Cold-PCR mutation detection technology to its portfolio

Angiochem to announce clinical study results of ANG1005 drug

Helicos Biosciences awarded a $2.9M NIH grant

Biotechnology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News